Shibu Kizhakevilayil
Mr. Shibu Kizhakevilayil resigned as a director of the Company, effective immediately.
Highest-materiality recent filing
Healthcare Triangle enters platform development deal with SecureKloud; budget $3.2M
Agreement with SKL and Blockedge to develop integrated health advisory & care platform and AI document management tools.
Acquired Teyamé 360 reports FY2025 revenue $17.2M, net profit $1.1M
Teyamé 360 revenue $17.16M in FY2025, down from $17.92M in FY2024 (-4%).
Offering of 421,553 shares and 260,000 pre-funded warrants at $5.81/share; gross proceeds ~$3.959M.
Healthcare Triangle effects 1-for-60 reverse stock split to meet Nasdaq $1 bid price rule
Reverse split effective Feb 10, 2026; shares reduced from ~45.4M to ~756,984.
Healthcare Triangle acquires Spanish AI CX firms for up to $50M; adds $32M annual revenue
Acquisition of Teyame 360 SL and Datono Mediacion SL, Spain-based AI omnichannel CX platforms.
Total consideration up to $50M: $15M cash, $6M common stock, $24M convertible preferred, $5M earnout.
Healthcare Triangle raises $6M via convertible notes with 20% OID; up to $15M total
Initial tranche $7.5M principal (20% OID, net $6M) to institutional investors; matures Nov 20, 2026.
Aggregate gross proceeds of ~$2.85M from cash exercise of up to 1,429,528 existing warrants at reduced $2.00/share.
Nasdaq determined HCTI regained compliance with Listing Rule 5635(a)(1) after amending acquisition agreement to condition share issuance on shareholder approval.
Healthcare Triangle 1-for-249 reverse stock split effective Aug 1, 2025 to meet Nasdaq $1 bid
Shares reduced from ~1.452B to ~5.83M; no fractional shares issued, rounded up.
Nasdaq Hearings Panel granted Healthcare Triangle continued listing on July 2, 2025, finding compliance with shareholders' equity rule and declining delisting.
Healthcare Triangle acquires Niyama Healthcare and Ezovion Solutions for $5.7M
Total consideration $5.7M includes $1.5M cash ($1.2M at close), $3M in restricted stock, up to $1.2M earn-out.
Nasdaq notifies Healthcare Triangle of delisting for low stock price and public interest concerns
Stock closed at $0.10 or less for 10 consecutive trading days, triggering the Low Priced Stocks Rule.
Nasdaq notifies HCTI of delisting over warrant dilution concerns
Nasdaq notified HCTI on May 20, 2025, of intent to delist under Rule 5101 due to public interest concerns from warrant reset provisions.
CFO Thyagarajan Ramachandran resigned effective April 10, 2025; not due to any disagreement with the company.
Healthcare Triangle closes $15.2M PIPE, regains Nasdaq equity compliance
Closed private placement of 36,190,485 units at $0.42/unit; gross proceeds $15.2M, net $13.68M.
Healthcare Triangle receives Nasdaq bid price deficiency notice; stock below $1 for 30 days
Closing bid price below $1.00 for 30 consecutive business days; 180-day cure period ends Aug 25, 2025.
Intangible assets lacking support written off up to $2.185M; goodwill and intangible of $1.289M and $4.3M moved to FY2022.
Healthcare Triangle receives Nasdaq delisting notice for failure to hold 2024 annual meeting
Received Nasdaq notice on Jan 14, 2025 for non-compliance with annual meeting requirement; no meeting held in 2024.
Healthcare Triangle regains Nasdaq minimum bid price compliance
Received Nasdaq deficiency notice on June 26, 2024 for bid price below $1.00.
Acquired cloud/tech assets from SecureKloud Technologies in exchange for 1.6M shares of Series B Convertible Preferred Stock, each convertible into 10 common shares subject to stockholder approval.
Acquired cloud and technology business assets of SecureKloud Technologies, Inc. for 1,600,000 shares of Series B Convertible Preferred Stock valued at $7.2 million.
Healthcare Triangle receives default notice from Seacoast; Interim CEO resigns
Received default notice from Seacoast on Sept 4, 2024 in connection with the Purchasing Agreement dated May 2, 2022.
Healthcare Triangle receives Nasdaq delisting notice; trading to suspend Sept 12 unless appeal
Nasdaq Staff determined Company did not meet extension terms for minimum $2.5M stockholders' equity requirement.
Nasdaq notifies HCTI of bid price non-compliance; 180-day cure period to Dec 23, 2024
Bid price closed below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
Healthcare Triangle dismisses BF Borgers as auditor after SEC Rule 102(e) order
Audit Committee approved dismissal of BF Borgers CPA PC as independent auditor on May 3, 2024.
Mr. Shibu Kizhakevilayil resigned as a director of the Company, effective immediately.
the Board appointed Ms. Sujatha Ramesh as an executive director of the Company, along with their current role as the Chief Operating Officer of the Company.
the Board of Directors (the “Board”) of the Company appointed Mr. David Ayanoglou to serve as the Company’s Chief Financial Officer, effective immediately.
On April 8, 2025, Mr. Thyagarajan Ramachandran informed the Company that they had decided to resign from their position as the Chief Financial Officer of the Company, effective April 10, 2025, along with the appointment of Mr. David Ayanoglou as the new Chief Financial Officer of the Company.
On March 18, 2025, the Board of Directors (the “Board”) of the Healthcare Triangle, Inc. (the “Company”) appointed Ms. Sujatha Ramesh to serve as the Company’s Chief Operating Officer, effective immediately.
On September 4, 2024, Anand Kumar, the Interim Chief Executive Officer (“CEO”) of the Company, resigned from his role as CEO, effective immediately to pursue other professional opportunities.
Max materiality 0.95 · Median 0.65 · Most common event other_material